Verici Dx Plc (VRCI) AI Stock Analysis

• Market Cap: £11.35M
• Dividend Yield: N/A
• Average Volume (3M): 6.85M
• Price to Earnings (P/E): ―
• Beta (1Y): -1.53
• Revenue Growth: -57.03%
• EPS Growth: -15.71%
• Country: UK
• Employees: 19
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 1,513,394,200
• 10 Day Avg. Volume: 9,044,876
• 30 Day Avg. Volume: 6,845,005
• PEG Ratio: 0.04
• Price to Book (P/B): 2.15
• Price to Sales (P/S): 3.38
• P/FCF Ratio: -1.82
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: 0.78p ▲(8.33% Upside)

Verici Dx Plc's overall stock score is driven by positive corporate events and technical indicators, which are offset by financial performance challenges and valuation concerns. The company's strategic initiatives and market expansion efforts are promising, but ongoing profitability and cash flow issues present significant risks.

Positive Factors

Business model (fee-for-service)

A fee-for-service model with hospitals and transplant centers creates a durable per-test revenue stream tied to clinical use. Institutional customers typically provide repeatable demand and predictable unit economics, supporting steady revenue scaling as adoption of transplant diagnostics grows.

Quality & compliance certifications

Passing CAP and ISO 27001 audits signals strong laboratory quality and data-security governance, reducing adoption friction with hospitals and partners. These certifications are lasting trust assets that support commercialization, regulatory acceptance and partnerships in precision diagnostics over the medium term.

Conservative capital structure

A low debt-to-equity profile gives the company financial flexibility and lower fixed charges, important for an R&D-intensive diagnostics firm. This conservatism reduces bankruptcy risk and preserves optionality for strategic investments or equity-funded growth during extended commercialization periods.

Negative Factors

Negative operating cash flow

Sustained negative operating and free cash flow indicates the core business doesn't yet generate sufficient cash, forcing dependence on external financing. That reliance can dilute shareholders or restrict investment in sales and product development until operations turn cash-positive.

Persistent operating losses

Repeated negative EBIT and net income show the company has not achieved profitability despite revenue activity. Long-term viability requires structural margin improvement, pricing scale or partnerships; otherwise ongoing losses will necessitate recurring funding and constrain strategic options.

Weak recent revenue trend

A large negative reported revenue growth rate signals deteriorating top-line momentum, which undermines scale economics and the ability to invest in commercialization. Persistent revenue declines increase the time and funding needed to reach sustainable operations and profitability.

Verici Dx Plc Business Overview & Revenue Model

Company Description

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.

How the Company Makes Money

Verici Dx generates revenue primarily through the sale of its diagnostic tests to hospitals, transplant centers, and healthcare providers. The company benefits from a fee-for-service model, where it charges healthcare institutions for each test performed. Additionally, Verici Dx may explore partnerships and collaborations with pharmaceutical companies and research institutions, which can provide further revenue opportunities through joint ventures, research grants, or co-development agreements. The expansion of its test offerings and the establishment of new relationships within the healthcare ecosystem are significant factors contributing to its earnings.

Verici Dx Plc Financial Statement Overview

Summary

Verici Dx Plc is experiencing revenue growth but continues to face profitability challenges, with ongoing net losses impacting return metrics. The balance sheet remains stable with low leverage, although cash flow issues persist due to negative operating cash flows, indicating the need for careful financial management and potentially further external financing.

Income Statement

Verici Dx Plc has shown a significant increase in total revenue from 2023 to 2024, indicating positive revenue growth. However, the company has consistently reported negative EBIT and net income figures, reflecting ongoing losses. The gross profit margin stands at 100% due to the absence of cost of goods sold, but negative net profit and EBIT margins highlight profitability challenges.

Balance Sheet

The company's balance sheet shows a strong equity position with a low debt-to-equity ratio, suggesting a conservative capital structure. However, the return on equity is negative due to net losses, which is a concern. The equity ratio indicates that a significant portion of the company's assets is financed by equity, which is a positive sign of financial stability.

Cash Flow

The cash flow statement reveals negative operating and free cash flow, indicating cash outflows from core operations. Financing activities have provided substantial cash inflows, suggesting reliance on external financing. The operating cash flow to net income ratio is negative, reinforcing cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.48M	3.34M	1.01M	0.00	0.00	0.00
Gross Profit	1.56M	3.34M	1.01M	0.00	0.00	0.00
EBITDA	-7.11M	-5.15M	-7.88M	-10.50M	-7.15M	-2.10M
Net Income	-6.91M	-5.87M	-8.73M	-11.36M	-8.33M	-7.10M
Balance Sheet
Total Assets	4.54M	7.49M	7.44M	14.30M	13.79M	20.31M
Cash, Cash Equivalents and Short-Term Investments	467.00K	4.06M	2.65M	9.80M	10.34M	17.75M
Total Debt	282.00K	371.00K	540.00K	700.00K	0.00	73.55K
Total Liabilities	2.06M	2.23M	3.88M	2.80M	1.80M	681.89K
Stockholders Equity	2.48M	5.26M	3.56M	11.51M	11.98M	19.62M
Cash Flow
Free Cash Flow	-6.37M	-6.21M	-7.39M	-11.38M	-7.30M	-1.32M
Operating Cash Flow	-5.55M	-6.02M	-7.16M	-10.07M	-6.34M	-1.28M
Investing Cash Flow	108.19K	61.00K	-231.00K	-1.31M	-965.86K	-237.16K
Financing Cash Flow	-282.64K	7.32M	-27.00K	12.67M	-73.55K	26.75M

Verici Dx Plc Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.72
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VRCI, the sentiment is Neutral. The current price of 0.72 is below the 20-day moving average (MA) of 0.78, below the 50-day MA of 0.76, and below the 200-day MA of 1.02, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 46.26 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:VRCI.

Verici Dx Plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VRCI	58 Neutral	£11.35M	-0.31	-122.54%	―	-57.03%	-15.71%
BSFA	56 Neutral	£2.44M	-1.30	-46.41%	―	-64.18%	12.05%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRM	46 Neutral	£9.45M	-2.83	―	―	12.19%	18.12%
ABDX	45 Neutral	£15.69M	-6.58	-90.48%	―	37.39%	-126.19%
GDR	44 Neutral	£9.01M	-0.94	-153.92%	―	90.42%	79.21%
GENI	41 Neutral	£5.59M	-0.84	-181.41%	―	12.12%	54.24%

Verici Dx Plc Corporate Events

Verici Dx Achieves Successful CAP Accreditation Audit

Verici Dx Plc has successfully completed its second biennial CAP accreditation audit for its clinical laboratory, demonstrating its commitment to maintaining high standards in clinical laboratory practices. This accreditation ensures that Verici Dx can consistently provide reliable test results, reinforcing its position as a trusted partner to clinicians and enhancing personalized care for kidney transplant patients.

The most recent analyst rating on (GB:VRCI) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.

Verici Dx Expands Reach with Prime Health Services Agreement

Verici Dx Plc has entered into a Provider Participation Agreement with Prime Health Services, a leading US-based healthcare technology company with a vast Preferred Provider Organization network. This agreement is a significant step for Verici Dx, as it expands its commercial reach and patient network, enhancing its coverage from private payors and potentially increasing its market presence in the healthcare diagnostics sector.

The most recent analyst rating on (GB:VRCI) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.

Verici Dx Achieves ISO 27001 Audit Success, Enhancing Industry Trust

Verici Dx Plc has successfully completed its annual ISO 27001:2022 surveillance audit, reaffirming its commitment to data privacy and security. This achievement strengthens its reputation as a trusted partner in the organ transplant diagnostics industry, ensuring compliance with global standards and maintaining stakeholder confidence.

The most recent analyst rating on (GB:VRCI) stock is a Hold with a £1.00 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.

Verici Dx Plc Revises and Expands Share Options to Align with Market Conditions

Verici Dx Plc has announced a revision of its share options, adjusting the exercise price of existing options and granting new options to directors, employees, and consultants. This move aims to realign incentives with current market conditions and ensure alignment between the interests of the company’s stakeholders and its leadership, following a decrease in share price and recent fundraising activities.

The most recent analyst rating on (GB:VRCI) stock is a Hold with a £1.00 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.